RSM helps biopharmaceutical company save IPO price
Rapid valuation response helps client finance its future
A biopharmaceutical company had developed next generation cardiac and pulmonary therapies and was ready to move on to clinical trials in the U.S. and a product launch in Europe, but they were running out of cash. They had to complete an IPO – and quickly.
They turned to RSM. Under very tight deadlines, we:
- completed nine different valuations
- helped the client coordinate the process with their management, auditors and legal counsel
- helped the client draft its S-1 and answer SEC queries
Learn more about how we helped this client move on with its IPO quickly and finance its future.